CA2340593C - Use of vegf-c or vegf-d gene or protein to prevent restenosis - Google Patents

Use of vegf-c or vegf-d gene or protein to prevent restenosis Download PDF

Info

Publication number
CA2340593C
CA2340593C CA2340593A CA2340593A CA2340593C CA 2340593 C CA2340593 C CA 2340593C CA 2340593 A CA2340593 A CA 2340593A CA 2340593 A CA2340593 A CA 2340593A CA 2340593 C CA2340593 C CA 2340593C
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
vegf
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2340593A
Other languages
English (en)
French (fr)
Other versions
CA2340593A1 (en
Inventor
Kari Alitalo
Mikko O. Hiltunen
Markku M. Jeltsch
Marc G. Achen
Seppo Yla-Herttuala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Vegenics Pty Ltd
Helsinki University Licensing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd, Helsinki University Licensing Ltd filed Critical Vegenics Pty Ltd
Publication of CA2340593A1 publication Critical patent/CA2340593A1/en
Application granted granted Critical
Publication of CA2340593C publication Critical patent/CA2340593C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2340593A 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis Expired - Fee Related CA2340593C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
US60/105,587 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (2)

Publication Number Publication Date
CA2340593A1 CA2340593A1 (en) 2000-05-04
CA2340593C true CA2340593C (en) 2012-05-08

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2340593A Expired - Fee Related CA2340593C (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Country Status (12)

Country Link
EP (1) EP1126870B1 (https=)
JP (2) JP4769929B2 (https=)
CN (1) CN1338943A (https=)
AT (1) ATE275417T1 (https=)
AU (1) AU768330B2 (https=)
CA (1) CA2340593C (https=)
DE (1) DE69920031T2 (https=)
ES (1) ES2229788T3 (https=)
NO (1) NO20012017L (https=)
NZ (1) NZ510121A (https=)
PT (1) PT1126870E (https=)
WO (1) WO2000024412A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
ATE481097T1 (de) * 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
AU2003224587A1 (en) * 2002-04-30 2003-11-17 Fit Biotech Oyj Plc Medical device
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
WO2005039556A1 (ja) * 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
WO2005089822A1 (ja) * 2004-03-18 2005-09-29 Kensuke Egashira 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
IL286675B2 (en) * 2019-03-29 2026-02-01 Abiomed Inc Systems and methods for left ventricular unloading in biological therapy or vector gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
EP0977854A2 (en) * 1997-04-25 2000-02-09 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
EP1126870A2 (en) 2001-08-29
AU768330B2 (en) 2003-12-11
EP1126870B1 (en) 2004-09-08
NO20012017L (no) 2001-06-26
NO20012017D0 (no) 2001-04-24
JP4769929B2 (ja) 2011-09-07
JP5231587B2 (ja) 2013-07-10
PT1126870E (pt) 2005-01-31
AU1314700A (en) 2000-05-15
JP2011173874A (ja) 2011-09-08
ES2229788T3 (es) 2005-04-16
CA2340593A1 (en) 2000-05-04
CN1338943A (zh) 2002-03-06
DE69920031D1 (de) 2004-10-14
WO2000024412A3 (en) 2000-08-03
JP2002528420A (ja) 2002-09-03
ATE275417T1 (de) 2004-09-15
DE69920031T2 (de) 2005-09-22
WO2000024412A2 (en) 2000-05-04
NZ510121A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
CA2340593C (en) Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6958147B1 (en) Use of VEGF-C to prevent restenosis
KR100695590B1 (ko) 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
US5851521A (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
EP0892644B1 (en) In vivo gene transfer methods for wound healing
CA2392284C (en) Medical device
US7563278B2 (en) Drug-eluting intravascular prostheses and methods of use
JP2000505780A (ja) 血管損傷の処置
JP2004537344A (ja) 医療装置
Maillard et al. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries
US20120308522A1 (en) Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia
EP1568375A1 (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
AU2004201020A1 (en) Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis
Asahara et al. Molecular and cellular cardiology: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
Meyerson et al. Gene therapy as a therapeutic intervention for vascular disease
Klocke et al. Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-angioplasty
Makeev et al. THE NEW WAY TO THE GENE THERAPEUTIC CORRECTION OF THE PATHOGENETIC MECHANISMS OF CORONARY INSUFFICIENCY
HK1108845B (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
Meyerson et al. Gene therapy for cardiovascular disease
MXPA99004088A (en) Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
Kingston Gene Therapy for Restenosis: Assessment of the Effects on Luminal Loss of Two Gene Therapy Strategies to Antagonise Transforming Growth Factor-β1 After Coronary Angioplasty
AU2002303052A1 (en) Medical device

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141027